- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-1827
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Biomarkers of response to PD-1 pathway blockade ; volume:126 ; number:12 ; day:28 ; month:2 ; year:2022 ; pages:1663-1675 ; date:6.2022
British journal of cancer ; 126, Heft 12 (28.2.2022), 1663-1675, 6.2022
- Creator
-
Li, Hanxiao
van der Merwe, P. Anton
Sivakumar, Shivan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-022-01743-4
- URN
-
urn:nbn:de:101:1-2022080419523748619150
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Li, Hanxiao
- van der Merwe, P. Anton
- Sivakumar, Shivan
- SpringerLink (Online service)
Other Objects (12)
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
PD ‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFNγ Responses of HIV-Infected Persons on Antiretroviral Therapy
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/PD ‐1 blockade therapy
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
PD ‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFNγ Responses of HIV-Infected Persons on Antiretroviral Therapy
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/PD ‐1 blockade therapy
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
PD ‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFNγ Responses of HIV-Infected Persons on Antiretroviral Therapy
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/PD ‐1 blockade therapy
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders